Possibilities of Adding Pulmonary Surfactant to Comprehensive Therapy of Patients with Respiratory Tuberculosis: Results of a Prospective Comparative Study
https://doi.org/10.58838/2075-1230-2024-102-4-70-77
Abstract
The objective: to assess effectiveness and safety of the surfactant as part of comprehensive anti-tuberculosis therapy in pulmonary tuberculosis patients depending on the drug resistance pattern and HIV status.
Subjects and Methods. 184 patients with pulmonary tuberculosis were enrolled in the study, of them 130 (70.7%) were men and 54 (29.3%) were women. All patients were randomized into Main Group (MG) and Control Group (CG). Surfactant therapy was added to comprehensive anti-tuberculosis therapy of the patients from Main Group. Additionally, each group was divided into subgroups based on HIV status.
Results. The addition of surfactant therapy to comprehensive anti-tuberculosis therapy increases effectiveness of treatment improving such parameters as sputum conversion and cavity healing regardless of drug susceptibility pattern including patients with concomitant HIV infection. At the same time, the agent used for surfactant therapy demonstrated good tolerability.
About the Authors
Yu. I. Timakova
Moscow Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Yulia I. Timakova, Deputy Head of Medical Department, Clinic no. 1
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7(496) 588-41-29
M. A. Plekhanova
Moscow Regional Clinical TB Dispensary; M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Maria A. Plekhanova, Doctor of Medical Sciences, Deputy Head Physician for Research, Professor of Phthisiology Department
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7(496) 588-41-29
N. V. Chiginok
Moscow Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Natalia V. Chiginok, Head of Therapy Department, Sukmanikha Hospital
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7(496) 588-41-29
T. R. Bagdasaryan
Moscow Regional Clinical TB Dispensary; M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Tatevik R. Bagdasaryan, Candidate of Medical Sciences, Head of Clinic no. 1, Associate of Phthisiology Department
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7(496) 588-41-29
A. A. Glotov
Moscow Regional Clinical TB Dispensary; M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Aleksey A. Glotov, Doctor of Medical Sciences, Head of the Endoscopy Department, Clinic no. 1, Professor of Phthisiology Department
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7(496) 588-41-29
References
1. Vasilyeva I.A., Samoylova A.G., Zimina V.N., Lovacheva O.V., Abramchenko A.V.. Chemotherapy for tuberculosis in Russia – the story continues. Tuberculosis and Lung Diseases, 2023, vol. 101, no. 2, pp. 8-12. (In Russ.)
2. Glants S. Mediko-biologicheskaya statistika. [Medical biological statistics]. Moscow, Praktika Publ., 1998.
3. Erokhin V.V., Lepekha L.N., Erokhin M.V., Lovacheva O.V. Surfaktantnaya sistema legkikh pri tuberkuleze. [Lung surfactant system in tuberculosis]. Moscow, New Terra Publ., 2013.
4. Zhukova E.M., Stavitskaya N.V., Pushkareva E.Yu., Smolentseva O.A. Inhalation surfactant therapy within comprehensive treatment of HIV-infected patients with multiple drug resistant tuberculosis. Tuberculosis and Lung Diseases, 2023, vol. 101, no. 1S, pp. 32-38. (In Russ.)
5. Surfaktant-BL. [Surfactant-BL]. Available: https://www.rlsnet.ru/drugs/surfaktant-bl-14675 Accessed June 20, 2024
6. Federalnye klinicheskiye rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya s mnozhestvennoy i shirokoy lekarstennoy ustoichivostyu vozbuditelya. [Federal clinical guidelines for diagnosis and treatment of respiratory tuberculosis with multiple and extensive drug resistance]. Rossiyskoe Obschestvo Ftiziatrov Publ. Available: http://roftb.ru/netcat_files/doks2015/rec2.pdf Accessed June 20, 2024
7. Gopal R., Rapaka R.R., Kolls J.K. Immune reconstitution inflammatory syndrome associated with pulmonary pathogens. Eur. Respir. Rev., 2017, vol. 26, no. 143, pp. 160042.
8. Pondman K.M., Paudyal B., Sim R.B., Kaur A., Kouser L., Tsolaki A.G., Jones L.A., Salvador-Morales C., Khan H.A., Ten Haken B., Stenbeck G., Kishore U. Pulmonary surfactant protein SP-D opsonises carbon nanotubes and augments their phagocytosis and subsequent pro-inflammatory immune response. Nanoscale, 2017, vol. 9, no. 3, pp. 1097-1109.
9. Raffetseder J., Iakobachvili N., Loitto V., Peters P.J., Lerm M. Retention of EsxA in the capsule-like layer of mycobacterium tuberculosis is associated with cytotoxicity and is counteracted by lung surfactant. Infect. Immun., 2019, vol. 87, no. 3, pp. e00803-18.
10. Zhao J.W., Jiao L., Guo M.M., Zheng L., Wang X.B., Gao S.H., Ying B.W., Ming L. SFTPC genetic polymorphisms are associated with tuberculosis susceptibility and clinical phenotype in a Western Chinese Han population. Exp. Ther. Med., 2020, vol. 20, no. 5, pp. 100.
Review
For citations:
Timakova Yu.I., Plekhanova M.A., Chiginok N.V., Bagdasaryan T.R., Glotov A.A. Possibilities of Adding Pulmonary Surfactant to Comprehensive Therapy of Patients with Respiratory Tuberculosis: Results of a Prospective Comparative Study. Tuberculosis and Lung Diseases. 2024;102(4):70-77. (In Russ.) https://doi.org/10.58838/2075-1230-2024-102-4-70-77
Views:
209
Email this article 